Group Purchasing | Utilize AT Conference to Cut the Cost of Your Phone and Web Conferencing Great Savings - SoCalBio Special Rate of 5¢/minute |
Join SoCalBioJoin well-known entrepreneur Alfred Mann and other SoCalBio leaders to promote the biotech and device industries in the Greater Los Angeles Metro Area for job creation and overall economic growth. |  |
Looking for Experts to Help You Craft PR, Communicaton and Branding Strategies?  | |
| Recommended Events MDMA Annual MeetingJune 1 - 3  --------------------------------------Personalized Medicine Today and Tomorrow
Date: June 9, 2009
Time: 5:30 p.m. - 8:00 p.m. Pfizer La Jolla
Building CB4 Patio
10646 Science Center Drive
San Diego, CA ------------------------------ --------
| 
Register Now |
Enhance your Career BIOTECH DEMYSTIFIED The Science Behind the Business
June 8-10, 2009
Rady Center for Executive Development, UC San Diego
San Diego, CA
| MOMENTUM WEEKEND FOR WOMEN IN LIFE SCIENCES June 11-14, 2009 Keck Graduate Institute Learn more LIFE SCIENCE
ENTREPRENEUR'S
BUSINESS LAW
PRIMER
Thomas Jefferson School of Law, San Diego |
|
| 
| May 26, 2009 |
| Thanks to Lead SoCalBio Sponsor |  |
Industry Snapshot | The Medical Aesthetics Industry in Los Angeles, Orange County and Neighboring Communities
The aesthetic medicine market generated $34 billion in 2008 - up ~ 36% from 2007. Southern California is home to many of the leading companies in this market segment including Allergan in Irvine, Inamed (now Allergan Medical) and Mentor Corp. in Santa Barbara, and Obagi Medical Products in Long Beach. |
RSVP Now for SoCalBio Events | May 28, 4:00 - 7:30 pm June 4, 11 to 2 - June 12, 7:30 am - 5:30 pm
June 16, 10:00 am - 4:00 pm - June 19, 11 to 2
June 25, 7:00 - 9:30 am September 17, 7:00 am - 7:00 pm
|
| Venture Funding | Clouds Clearing:
Venture activity and private equity picking up steam as public markets remain dry Public markets remain dry, but companies raising venture capital and private equity financings are having quite a bit of success. Small U.S. public companies are tapping the private markets and seem to be especially fond of registered direct offerings, with six of the nine PIPEs completed during the week structured in this manner... Read more |
| M&As |  Johnson & Johnson has snagged a biotech with a late-stage oncology drug for prostate cancer. Cougar will work with Ortho Biotech Oncology R&D, a unit of Centocor R&D. Cougar is conducting two Phase III trials for abiraterone acetate for prostate cancer. Alan Auerbach (photo right), CEO of Cougar Biotechnology, said: "Since the founding of Cougar approximately six years ago, our employees have been relentlessly dedicated to the development of oncology drugs and the creation of shareholder value. We believe that this transaction strongly positions abiraterone acetate for future success with a leading healthcare company that has the expertise, resources, dedication and motivation to deliver it to the cancer patients who need it."... Read more Related: |
| Collaborations | Amgen Gets Rights to Cytokinetics Heart Failure Drug Cytokinetics (South San Francisco) will get $50 million from Amgen and up to $600 million in future payments upon the success of the drug.... Read more |
| Grant Funding | Molecular Express of Dominguez Hills Announces Award of SBIR Phase II Funding from the National Heart Lung and Blood Institute to Develop a Synthetic Lung Surfactant
The lung surfactant project will be a multi-institutional collaborative effort between Professors Alan Waring and Frans Walther of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ( LA BioMed), Professor Robert Notter of the University of Rochester, Professor Adrian Schwan of the University of Guelph and the Molecular Express team. The Company has also obtained an exclusive license to certain synthetic lung surfactant technology discovered by Professors
Waring, Walther, Notter and Schwan... Read more |
| Patents | Viral Genetics of San Marino Has Option Under Issued Key Patent for Cancer Drug "This patent represents the first method for treating drug resistant cancer using metabolic disruption, an approach targeting the distinct cancer-specific metabolic activities that can distinguish cancer cells in general, and many drug resistant cancer types, in specific, from normal cells in normal tissues," said M. Karen Newell, PhD., tenured professor at the University of Colorado, Colorado Springs. Viral Genetics has certain exclusive licenses and options from the University of Colorado under previously filed patent rights, the work by Dr. M. Karen Newell and her group. Viral Genetics' licenses and options with the University are in return for certain obligations and fees... Read more |
| New Products | Camera Phones to Interpret Visible World for Blind iVisit, a company out of Santa Monica, California that specializes in video teleconferencing applications, has teamed up with the National Institutes of Health to turn a mobile phone's camera into an eye for the blind. Using advanced image recognition software to identify what is in front of the phone, the system reads off what it is seeing... See a demo | Watson Pharmaceuticals of Corona, Calif. Launches
GELNIQUE, the First and Only Topical Gel for Overactive Bladder (OAB) While GELNIQUE is approved for use in men as well as women, Watson has opted to target the active, female OAB patient in its marketing efforts. The GELNIQUE marketing campaign will highlight the power of control GELNIQUE offers to OAB patients rather than focusing, as traditional products have, on the predictable embarrassment and stigma associated with OAB ... Read more |
| People | Marty J. Duvall Joins Abraxis BioScience as Senior Vice President, Global Marketing and International Commercial Operations Mr. Duvall (photo right) most recently served as Chief Business Officer,
Morphotek, a subsidiary of Eisai Corporation of North America, following Eisai's acquisition of MGI
PHARMA, INC., where he served as Sr. Vice President, Commercial Operations (2004-2006) and Sr. Vice President, Commercial Strategy and Development (2007-2008)... Read more NanoPacific Holdings Announces Appointment of UCLA Chancellor Emeritus, Albert
Carnesale, Ph.D. to its Board of Directors  "I am excited by NanoPacific's capacity to develop and apply nanotechnologies in creative yet practical ways. It is a privilege to join this team of outstanding scientists, engineers, and business leaders," commented Carnesale (photo right). NanoPacific is a privately held research and development company based in Los Angeles and focused on commercializing a patented nanotechnology portfolio which it has exclusively licensed from UCLA, and the Regents of the University of California... Read more Simulations Plus Appoints Michael
Pelekis, Ph.D., Director for Business Development  Walt Woltosz (photo right), chairman and CEO of the Lancaster, Calif.-based Simulations Plus: "We're extremely pleased that Michael has joined the Simulations Plus team. Michael comes to us with 20 years of experience in the pharmaceutical and environmental toxicology industries" ... Read more |
| Jobs | - Alfred Mann Institute at USC (Los Angeles):
- Allergan (Irvine):
- Allergan Medical (Santa Barbara):
- Edwards Lifesciences (Irvine):
- Norac Pharma (Azusa):
- STAAR Surgical (Monrovia):
- Watson Pharmaceuticals (Corona):
|
About SoCalBio |  SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio |
| Editor: Ahmed A. Enany Southern California Biomedical Council (SoCalBio) |
|
|
